Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Nephrology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters
 

Chronic Renal Anemia Clinical Trials

A listing of Chronic Renal Anemia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (11) clinical trials

The primary objective of this study is to evaluate the cardiovascular (CV) safety of anemic patients with Stage 3, 4 or 5 chronic kidney disease (CKD) who are not on dialysis. The treatment period is anticipated to be 1-2 years. You will be compensated for each study visit completed, up ...

Phase

Iron deficiency anemia is a type of anemia that commonly occurs after significant blood loss from a disease or medical condition. The loss of iron means your body can't carry enough oxygen, which often leaves you tired and breathless. In this study participants who have been diagnosed with chronic kidney ...

Phase

Ferric Citrate for the Transition From CKD Stage 4/5 to CKD Stage 5D

This is an up to 50 week, phase 3, clinical trial in patients with estimated glomerular filtration rate (eGFR) ≤ 20 ml/min/1.73m2. It will be comprised of an up to 36-week non-dialysis period (NDP), or until such time as subjects require renal replacement therapy (RRT) with dialysis when they will ...

Phase

Safety and Efficacy Study of BCD-066 Compared to Aranesp for Anemia Treatment in Chronic Kidney Disease Patients

In this study CKD patients on dialysis previously treated by short-acting epoetins will switch to one of darbepoetin alfa products - BCD-066 (experimental arm) or Aranesp (active comparator) to maintain previously achieved target level of hemoglobin (100-120 g/l). Patients will be treated for 52 weeks. IV iron supplementation will be ...

Phase

Intravenous Iron in Patients With Severe Chronic Heart Failure and Chronic Kidney Disease

Intravenous iron administration in CHF patients with absolute or functional iron deficiency could correct their anemia, thus improving cardiac function judged by ejection fraction and NYHA functional class. If true, enhancement of cardiac output will increase oxygen delivery to tissues, including renal cortex. This might improve the renal functions and ...

Phase

A Study of Intermittent Oral Dosing of ASP1517 in Non-Dialysis Chronic Kidney Disease Patients With Anemia

This study consists of the following three cohorts. Cohort 1; subjects converted from rHuEPO or DA to ASP1517, Cohort 2; subjects converted from rHuEPO or DA to DA, Cohort 3; subjects converted from epoetin beta pegol (CERA) to ASP1517. In Cohort 1 and 3, ASP1517 will be administered orally for ...

Phase